A retrospective study of Vemurafenib assessing clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation
Latest Information Update: 29 Dec 2021
At a glance
- Drugs Vemurafenib (Primary) ; Antineoplastics
- Indications Langerhans cell histiocytosis
- Focus Therapeutic Use
Most Recent Events
- 29 Dec 2021 New trial record
- 01 Dec 2021 Results published in the International Journal of Hematology